prikaz prve stranice dokumenta Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma
  Preuzmi
PDF 1.25 MB
Znanstveni rad - Izvorni znanstveni rad
Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma
BioMed Research International, 2014 (2014); 513170. https://doi.org/10.1155/2014/513170
Valković, Toni; Babarović, Emina; Lučin, Ksenija; Štifter, Sanja; Aralica, Merica; Pećanik, Sanja; Seili-Bekafigo, Irena; Duletić-Načinović, Antica; Nemet, Damir; Jonjić, Nives

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Valković, T., Babarović, E., Lučin, K., Štifter, S., Aralica, M., Pećanik, S. ... Jonjić, N. (2014). Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma. BioMed Research International, 2014.. doi: 10.1155/2014/513170

Valković, Toni, et al. "Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma." BioMed Research International, vol. 2014, 2014. https://doi.org/10.1155/2014/513170

Valković, Toni, Emina Babarović, Ksenija Lučin, Sanja Štifter, Merica Aralica, Sanja Pećanik, Irena Seili Bekafigo, Antica Duletić Načinović, Damir Nemet i Nives Jonjić. "Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma." BioMed Research International 2014 (2014). https://doi.org/10.1155/2014/513170

Valković, T., et al. (2014) 'Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma', BioMed Research International, 2014. doi: 10.1155/2014/513170

Valković T, Babarović E, Lučin K, Štifter S, Aralica M, Pećanik S, i sur.. Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma. BioMed Research International [Internet]. 2014. [pristupljeno 29.12.2024.];2014. doi: 10.1155/2014/513170

T. Valković, et al., "Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma", BioMed Research International, vol. 2014, 2014. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:358750. [Citirano: 29.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:358750
Podaci o radu
Naslov (engleski)Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma
AutorToni Valković
AutorEmina Babarović
AutorKsenija Lučin
AutorSanja Štifter
AutorMerica Aralica
AutorSanja Pećanik
AutorIrena Seili-Bekafigo
AutorAntica Duletić-Načinović
AutorDamir Nemet
AutorNives Jonjić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za opću patologiju i patološku anatomiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Patologija
Sažetak (engleski)
The aim of this pilot study was to determine the plasma levels of osteopontin (OPN) and vascular endothelial growth factor (VEGF) and find possible association between them and main clinical features and parameters of tumor burden in patient with multiple myeloma (MM). Plasma levels of OPN and VEGF were determined in 44 newly diagnosed MM patients and 24 healthy persons by ELISA method. These values were compared with the presence of anemia, renal dysfunction, and bone lesions as myeloma related clinical manifestations and with serum beta-2 microglobulin and Durie-Salmon clinical stage as prognosticators related to tumor mass. The value of OPN was significantly higher in MM patients with evident bone lesions () and there was also a positive correlation with serum beta-2 microglobulin (; ). Furthermore, patients with lower Durie-Salmon stage had significantly lower OPN and VEGF levels (; , resp.). Our preliminary results found positive association between plasma level of OPN, tumor burden, and bone destruction. Further analysis should provide information about the possible use of OPN as useful clinical biomarker for monitoring bone disease and tumor mass, as well as a prognostic factor, or a possible target for pharmacological intervention.
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaBioMed Research International
Brojčani podacivol. 2014, 513170
p-ISSN2314-6133
e-ISSN2314-6141
DOIhttps://doi.org/10.1155/2014/513170
URN:NBNurn:nbn:hr:184:358750
Datum objave publikacije2014
ProjektŠifra: 062-0620095-0079
Naziv (hrvatski): Uloga kemokina u patogenezi multiplog mijeloma
Voditelj: Toni Valković
Pravna nadležnost: Hrvatska
Financijer: MZOS
Linija financiranja: ZP
URL dokumentahttp://dx.doi.org/10.1155/2014/513170
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2017-09-20 21:43:47